TCS Launches Agentic AI Platform for Drug Development

TCS has launched TCS ADD AgentHub, an enterprise AI platform designed to help pharmaceutical companies deploy agentic AI across clinical development and pharmacovigilance while meeting regulatory and audit requirements.

The platform is built for highly regulated pharma environments, where fragmented systems, growing data volumes, and increasing regulatory expectations have made scaling AI across research and development workflows challenging. TCS said AgentHub allows companies to create and deploy AI agents with defined roles, human oversight, and built-in auditability.

According to TCS, solutions powered by the platform have delivered up to 40% efficiency gains in clinical data management, reduced clinical study build effort by up to 30% through metadata-driven automation, and generated up to 30% cost savings in end-to-end safety case processing. AI-powered safety agents can also cut quality-control effort by as much as 50%, the company said.

AgentHub supports workflows including individual case safety report intake, data entry, coding and review, literature analysis, study design, protocol digitisation, clinical data review, SDTM transformation, and medical monitoring assistance. TCS said its catalogue of AI agents can be deployed progressively based on an organisation's requirements, with minimal integration and implementation effort.

The platform follows a human-plus-AI operating model, in which AI agents are embedded into enterprise workflows while humans retain responsibility for governance and decision-making.

“TCS ADD AgentHub is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale,” said Debashis Ghosh, President, Lifesciences and Healthcare, TCS. He added that TCS aims to move towards autonomous enterprise functions where AI agents work alongside humans to drive innovation in drug development and improve patient safety.